PTAB challenges

Proceedings Overview

There are no Inter Partes Review (IPR), Post-Grant Review (PGR), or Covered Business Method (CBM) trial proceedings on file with the Patent Trial and Appeal Board (PTAB) for U.S. Patent 7,193,986 based on available data. Therefore, the patent has not been subjected to the types of AIA trial proceedings that would result in claims being upheld or invalidated by the PTAB.

However, it is critical to note that the patent is undergoing an ex parte reexamination (not an AIA trial proceeding). In this reexamination, the USPTO has indicated its intent to cancel several claims, including the independent claims. This development significantly impacts the patent's enforceability.

Ex Parte Reexamination of U.S. Patent 7,193,986

• Type: Ex Parte Reexamination
• Filed: July 28, 2025 (by Unified Patents)
• Status: Notice of Intent to Issue Reexamination Certificate issued, indicating claims 1-3, 5-6, and 8-9 are to be canceled.
• Petition grounds: The ex parte reexamination was initiated by Unified Patents, presumably on grounds of unpatentability under 35 U.S.C. §§ 102 and/or 103 based on prior art. While specific art and detailed reasoning are typically found in the reexamination file, the prior art analysis conducted previously for this patent (referencing U.S. 6,795,418 B2, U.S. 6,088,337 A, U.S. 6,498,936 B1, U.S. 6,947,446 B2, and US 2002/0115458 A1) suggests potential grounds for cancellation.
• Intent to Issue Reexamination Certificate: On April 3, 2026, the USPTO's Central Reexamination Unit (CRU) issued a notice of its intent to issue a reexamination certificate that would cancel claims 1-3, 5-6, and 8-9.
• Defensive value: This is a highly significant development. If the reexamination certificate is issued as intended, independent claims 1 and 9, along with several dependent claims, will be canceled. Any infringement theory relying on these claims would be significantly weakened, if not entirely eliminated. This provides a strong defensive posture against assertion of the patent, particularly for claims 1-3, 5-6, and 8-9.

Strategic Summary

As of May 29, 2026, U.S. Patent 7,193,986 has no formal AIA trial proceedings (IPR, PGR, CBM) on record with the PTAB. Therefore, none of its claims have been formally challenged or sustained through these specific mechanisms.

However, the patent has undergone an ex parte reexamination, which is a different form of USPTO administrative review. In this proceeding, the USPTO has issued an intent to cancel claims 1-3, 5-6, and 8-9. This means that independent claims 1 and 9 are slated for cancellation, along with several dependent claims (2, 3, 5, 6, 8). The claims currently sustained by this reexamination (i.e., not indicated for cancellation) would be claim 4 and claim 7. All other claims, if any, remain untested by this specific proceeding. This outcome substantially narrows the scope of the patent, potentially rendering it unassertable on its broadest claims.

The estoppel landscape regarding AIA trials is not applicable, as no IPR, PGR, or CBM proceedings have taken place. However, the reexamination by Unified Patents indicates an active defensive strategy against this patent. Given the USPTO's intent to cancel the broad claims, it signals that the patent owner's ability to assert these claims in litigation is severely compromised.

Recommended Next Steps

• For a defendant facing assertion of this patent: Immediately confirm the final status of the ex parte reexamination for U.S. Patent 7,193,986. If the reexamination certificate has indeed issued, formally canceling claims 1-3, 5-6, and 8-9, any infringement allegations based on these claims are likely without merit. This outcome should be leveraged forcefully in defense, potentially through motions to dismiss or for summary judgment.
• Monitor the reexamination docket: Access the official docket for the ex parte reexamination (likely 90/016,xxx or similar, which should be available through the USPTO's Patent Center or Unified Patents' portal) to obtain the final reexamination certificate once it issues.
• Review surviving claims: Conduct a thorough analysis of the remaining claims (claims 4 and 7 as currently understood) to determine their scope and if any current or planned product functionality could still potentially infringe them.
• Absence of AIA trials: The lack of IPR, PGR, or CBM proceedings suggests that, for a defendant, the option of filing such a petition might still be available, particularly for any claims that were not targeted or canceled in the ex parte reexamination. However, given the ex parte reexamination's outcome, such a strategy might be unnecessary for the canceled claims and should be carefully weighed for the surviving claims against the patent's approaching expiration date (May 25, 2025).